Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
주식 순위 #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
주가
$17.15
마지막 동기화: 2026-08-03
시가총액
$6.51M
변동 (1일)
9.80%
변동 (1년)
289.77%
국가
US
거래 Galera Therapeutics, Inc. (GRTX)

카테고리

Galera Therapeutics, Inc. (GRTX)의 EPS
March 2026 기준 EPS TTM: $303.74
Galera Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $303.74입니다. 2023년 말에는 회사의 EPS가 $-1.33였으며, 이는 2022년의 EPS $-2.30와 감소입니다.
Galera Therapeutics, Inc.의 EPS 기록 (2017 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $303.74 -86,882.86%
2024 $-0.35 -73.68%
2023 $-1.33 -42.17%
2022 $-2.30 -32.35%
2021 $-3.40 14.09%
2020 $-2.98 42.58%
2019 $-2.09 71.31%
2018 $-1.22 7,770.97%
2017 $-0.02 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -94.30%
US
$27.74 -90.87%
NL
- -
CH
- -
KR
$13.70 -95.49%
BE